Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Breast Neoplasms, Breast Diseases, Ultra...
Phase Not Applicable
Enrollment 1380
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This single-center, retrospective, observational study aims to construct a standardized benchmark evaluation system for intelligent breast ultrasound image interpretation and to systematically assess the diagnostic performance of current mainstream multimodal artificial intelligence (AI) models. De-identified B-mode breast ultrasound images with confirmed pathological diagnoses will be retrospectively collected from the institutional archive (2018-2025) and supplemented with images from published open-access datasets. Expert radiologists with varying experience levels will independently annotate all images according to the American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS) v2025 criteria, including glandular tissue composition, lesion characterization (mass vs. non-mass lesion), morphological descriptors, and final BI-RADS classification. Baseline deep learning models (CNN-based ResNet-50 and Transformer-based USFM) will be trained to establish performance baselines and to stratify cases by diagnostic difficulty through cross-architecture consensus. Multiple multimodal large language models (MLLMs), including both general-purpose and medical-domain models, will then be evaluated via standardized API calls using BI-RADS-guided chain-of-thought prompts at temperature 0 for reproducibility. Primary endpoints include BI-RADS classification accuracy and diagnostic AUC for benign-malignant differentiation. Model robustness and safety will be assessed through out-of-distribution rejection testing, temperature-stability experiments, and thinking-mode ablation studies. This study adheres to the FLAIR and TRIPOD-LLM reporting guidelines.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Diagnostic Test: Multimodal AI Model Diagnostic Evaluation — Retrospective evaluation of de-identified breast ultrasound images by multiple AI systems, including baseline deep learning models (ResNet-50, USFM) and multimodal large language models, using standardized BI-RADS-guided chain-of-thought prompts via API. No patient contact or clinical decision-making is involved.

Primary Outcomes

  • Diagnostic Accuracy for Pathological Diagnosis (At study completion, approximately 12 months)
  • BI-RADS Classification Accuracy (At study completion, approximately 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-12
Completion: 2027-03-01
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: true
Enrollment: 1380 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking Union Medical College Hospital
Collaborators: Chinese Academy of Medical Sciences
Principal Investigators:
  • Qingli Zhu, MD (PRINCIPAL_INVESTIGATOR) - Peking Union Medical College Hospital
Contact Information
Study Contact:
Qingli Zhu, MD
+86 13621376699
zqlpumch@126.com
Yinglan Wu, MD
+86 15626121076
wuylan7@gmail.com
Qingli Zhu, MD
+86 13621376699
zqlpumch@126.com
Peking Union Medical College Hospital
Interventions
  • Diagnostic Test: Multimodal AI Model Diagnostic Evaluation — Retrospective evaluation of de-identified breast ultrasound images by multiple AI systems, including baseline deep learning models (ResNet-50, USFM) and multimodal large language models, using standardized BI-RADS-guided chain-of-thought prompts via API. No patient contact or clinical decision-making is involved.
Study Locations (1 sites)
Peking Union Medical College Hospital, Beijing, 100730 China
Eligibility Criteria
Inclusion Criteria: * B-mode breast ultrasound grayscale images from the institutional PACS database or from published open-access breast ultrasound datasets with documented original institutional ethics approval * Image quality adequate for clinical diagnosis with clear visualization of the region of interest * Pathological diagnosis confirmed (for benign and malignant lesion groups), or normal breast status confirmed by a senior radiologist with \>15 years of breast ultrasound experience (for the normal group) * Complete de-identification with removal of all personally identifiable information Exclusion Criteria: * Severely degraded image quality precluding meaningful BI-RADS assessment * Duplicate images from the same patient (only the most representative image retained per lesion) * Images with residual personally identifiable information after de-identification processing * Cases with ambiguous, disputed, or unavailable pathological results * Non-B-mode ultrasound images, including elastography, contrast-enhanced ultrasound, and Doppler imaging
Conditions Breast Cancer Early Stage Breast Cancer ...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Drug: Oncologic drugs administered for treatment of breast cancer — Data on oncologic drugs administered for treatment of breast cancer will be recorded
  • Drug: Oncologic drug administered for treatment of gynecologic cancer — Data on oncologic drugs administered for treatment of gynecologic cancer will be recorded

Primary Outcomes

  • DFS (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-03-22
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Principal Investigators:
  • Claudio Zamagni, MD (PRINCIPAL_INVESTIGATOR) - IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola
Contact Information
Study Contact:
Claudio Zamagni, MD
0512144548
zamagniclaudio.sper@aosp.bo.it
Cinzia Pizzirani, PhD
0512144447
cinzia.pizzirani@aosp.bo.it
Claudio Zamagni, MD
0512144548
zamagniclaudio.sper@aosp.bo.it
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Interventions
  • Drug: Oncologic drugs administered for treatment of breast cancer — Data on oncologic drugs administered for treatment of breast cancer will be recorded
  • Drug: Oncologic drug administered for treatment of gynecologic cancer — Data on oncologic drugs administered for treatment of gynecologic cancer will be recorded
Study Locations (1 sites)
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138 Italy
Eligibility Criteria
Inclusion Criteria: * Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic; * Patients who have received treatment for breast cancer or gynecologic cancer since January 2010; * Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data. Exclusion Criteria: * no exclusion criteria
Conditions Breast Cancer, Metastatic Triple-Negativ...
Phase PHASE2
Enrollment 55
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Eribulin — Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.
  • Drug: SDX-7320 — SDX-7320 at the dose of 49 mg/m2 SC on a Q14D basis
  • Other: Placebo — Placebo

Primary Outcomes

  • change in insulin resistance scores (HOMA-IR) (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-10-03
Completion: 2027-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: SynDevRx, Inc.
Principal Investigators:
  • Sherry Shen, MD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Sherry Shen, MD
646-888-5134
shens1@mskcc.org
Tiffany Trainia, MD
646-888-4558
Lauren Carcas, MD
954-837-1490
BAPTIST ALLIANCE - MCI (Data Collection Only)
Interventions
  • Drug: Eribulin — Eribulin 1.4 mg/m2 IV on days 1 and 8 of an every 21 day cycle.
  • Drug: SDX-7320 — SDX-7320 at the dose of 49 mg/m2 SC on a Q14D basis
  • Other: Placebo — Placebo
Study Locations (10 sites)
BAPTIST ALLIANCE - MCI (Data Collection Only), Miami, Florida 33143 United States
Emory University (Data Collection Only), Atlanta, Georgia 30322 United States
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey 07920 United States
Hackensack Meridian Health, Hackensack, New Jersey 07601 United States
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York 10065 United States
Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: * Male or female with histologically and/or cytologically confirmed diagnosis of triple-negative metastatic breast cancer defined as estrogen and progesterone receptor staining ≤10%; and HER2-negative defined as IHC 0 to 1+ at enrolling institution (note: if IHC is equivocal, non-amplified status by FISH is acceptable) * Advanced (local regionally recurrent, not amenable to curative therapy or surgery) or metastatic stage with up to 2 prior lines of therapy in the advanced or metastatic setting * Received prior anthracycline and taxane chemotherapy in the neoadjuvant, adjuvant, or metastatic settings and considered appropriate for treatment with single agent eribulin OR was otherwise ineligible to receive anthracycline and/or taxane per treating physician OR patients with de novo metastatic disease. * Evidence of metabolic dysfunction defined as HbA1c \> 5.5 and/or BMI ≥ 30 kg/m\^2 * Measurable disease per the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), OR at least one evaluable, predominantly lytic bone lesion * Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≤1. * Adult ≥18 at the time of informed consent and has provided written informed consent before the performance of any study-related activities and according to local guidelines. * Adequate bone marrow and organ function as defined by the following laboratory values (as assessed by local laboratory for eligibility): * Absolute neutrophil count (ANC) ≥ 1,000 µL * Platelet count ≥ 140,000 µL * Hemoglobin ≥9.0 g/dL: * Calcium (corrected for serum albumin) and magnesium ≤ Grade 1 according to National Cancer Institute (NCI) Common Terminology * Calculate Corrected Calcium if the albumin and/or serum calcium are not within normal limits: Corrected Calcium= Serum Calcium + 0.8 x \[(Normal Albumin) - Patient Albumin\] Normal Albumin value = 4.4g/dL Criteria for Adverse Events (CTCAE), version 5.0, and not considered by the Investigator to be clinically significant * Potassium within normal limits, with or without correction with supplements. * In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×the upper limit of normal (ULN). If the patient has liver metastases, ALT and AST ≤5×ULN. * Total bilirubin ≤1.5×ULN except for patient with Gilbert's syndrome who may only be included if the total bilirubin is ≤3.0×ULN or direct bilirubin ≤1.5×ULN * Creatinine ≤1.5 mg/dL. * Patient is, in the treating Investigator's opinion, willing and able to comply with the study requirements, including the ability to fast prior to treatment days. * If sexually active female of childbearing potential, willing to use a contraception method listed below: * Oral, intravaginal, or transdermal combined (estrogen and progesterone containing) hormonal contraception * Oral, injectable, or implantable progesterone-only hormonal contraception * Intrauterine device (IUD) * Intrauterine hormone-releasing system (IUS) * Bilateral tubal occlusion * Vasectomized partner with documentation of successful vasectomy. * Complete abstinence from heterosexual intercourse * If a sexually active male, willing to use barrier contraception (condoms) Exclusion Criteria: * Three or greater prior lines of therapy for metastatic TNBC * Known primary brain malignancy, brain metastases or active CNS pathology, any of which as determined by the treating Investigator * Currently participating in a study of an investigational agent * Body mass index \< 18.5 kg/m2 * Known hypersensitivity to SDX-7320 or eribulin * Established diagnosis of diabetes mellitus type I or uncontrolled or insulin-dependent type II. Uncontrolled is defined as fasting blood glucose \>140 mg/dL and/or HbA1c ≥8% * Use of combination antihyperglycemic therapy (single agent metformin on stable dose for at least 3 months prior to enrollment is allowable) * Concurrent malignancy or malignancy within 3 years of randomization, with the exception of adequately treated, basal or squamous cell carcinoma, nonmelanomatous skin cancer or curatively resected cervical cancer. * Uncontrolled human immunodeficiency virus (HIV) infection. (Testing is not mandatory.) * Evidence of uncontrolled active Hepatitis B or C infection * History of Stevens-Johnson Syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN), or other severe medication-related cutaneous reactions. * Any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, contraindicate patient participation in the clinical study (e.g., chronic active hepatitis, severe hepatic impairment). * Clinically significant, uncontrolled heart disease and/or recent cardiac events including any of the following: * History of angina pectoris, coronary artery bypass graft (CABG) symptomatic pericarditis, or myocardial infarction within 6 months prior to study entry. * History of documented congestive heart failure (New York Heart Association functional classification III-IV). * Documented cardiomyopathy. * Left ventricular ejection fraction (LVEF) \<45%, as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO). * History of any cardiac arrhythmias, (e.g., ventricular tachycardia), complete left bundle block, high grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third-degree AV block) supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months. * Uncontrolled hypertension, defined by a systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg, with or without antihypertensive medication. Initiation or adjustment of antihypertensive medication(s) is allowed prior to screening * Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome or any of the following: risk factors for torsades de pointe including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure or history of clinically significant/symptomatic bradycardia; concomitant medications with a known risk to prolong the QT interval and known to cause torsades de pointe that cannot be discontinued or replaced by safe alternative medications. * Bradycardia (heart rate less than 50 at rest), by electrocardiogram (ECG) or pulse. * Inability to determine the QT interval on the ECG (i.e., unreadable or not interpretable) or corrected QT (QTcF) \>450 msec for males and \>470 msec for females (using Fridericia's correction) during Screening, based on the mean of triplicate ECGs * Currently receiving any of the following medications and cannot be discontinued 7 days prior to the start of the treatment: Medications with a known risk to prolong the QT interval or induce Torsade de Pointes (TdP). CredibleMeds list of drugs known to cause TdP may be used as a reference for this study to determine which drugs are prohibited using the following link: https://crediblemeds.org/new-drug-list or a crediblemeds mobile application. °Herbal preparations/medications, with the exception of cannabinoids, CBD compounds, etc. * Participation in a prior investigational study within 14 days prior to the start of the study treatment or within 5 half-lives of study drug, whichever is longer. * History of acute pancreatitis within 1 year of Screening or past medical history of chronic pancreatitis * Pregnant patients
Conditions Breast Cancer, Sentinel Lymph Node, Brea...
Phase NA
Enrollment 350
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The treatment and prognosis of breast cancer (BC) are dependent on its molecular subtype and nodal burden. In early BCs with favourable molecular subtype, the incidence of axillary node involvement is low. However, these patients are still subjected to an axillary operation, which can result in additional cost, operating time and morbidities. Similarly, in patients with limited nodal burden of 1-2 metastatic nodes, there is emerging evidence that these patients may need sentinel lymph node biopsy (SLNB) only, instead of an axillary clearance (AC), which has more surgical morbidities. We aimed to determine if axillary surgery could be safely tailored in BC patients based on their molecular subtype and nodal burden, without compromising their oncological outcomes. This could in turn reduce the morbidities associated with the axillary surgery, Total 350 patients will be enrolled. 50 patients with early BC and favourable molecular subtype will be enrolled in a pilot study A (SentiOMIT), whereby SLNB is omitted. For eligible patients who declined study A and other stage I-II patients, with preoperative N0 status, undergoing upfront surgery but did not meet the inclusion criteria of Study A, these patients will be enrolled into study B (SentiMACRO) to undergo SLNB. In study B, the patients will be categorized based on SLNB into 3 groups with 100 patients in each arm: B1 with pN0, B2- 1-2 metastatic nodes and B3- \>/=3 metastatic nodes. In Study B, we aim to investigate if the B2 group (100 patients) can be treated with a less invasive procedure of SLNB alone instead of AC, without affecting oncological outcomes. B1 and B3 are controls. The outcomes for study A and B include short term outcomes such as morbidity rates, cost and operating time savings. Long term outcomes include recurrence and survival rates. This study will allow individualisation of axillary surgery based on the patient's molecular subtype and nodal burden, to benefit patients' care.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Procedure: omission of SLNB in SentiOMIT or omission of ALND in SentiMACRO — Omission of SLNB in cT1-2N0 or Omission of ALND in patients with \</= 2 macrometastasis in SLNB

Primary Outcomes

  • short term outcomes (from date of surgery, assessed up to 6 months after operation)
  • short term outcomes (from date of surgery, assessed up to 1 months after operation)
  • short term outcomes (from date of surgery, assessed up to 1 months after operation)
  • long term outcomes (from date of surgery, assessed up to 5 years after operation)
  • long term outcomes (from date of surgery, assessed up to 5 years after operation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-06
Completion: 2033-12-31
Eligibility
Age: 21 Years – 80 Years
Sex: FEMALE
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: KK Women's and Children's Hospital
Contact Information
Study Contact:
Geok hoon Lim
96392353
lim.gh@singhealth.com.sg
Geok H Lim
lim.gh@singhealth.com.sg
KK Women's and Children's Hospital
Interventions
  • Procedure: omission of SLNB in SentiOMIT or omission of ALND in SentiMACRO — Omission of SLNB in cT1-2N0 or Omission of ALND in patients with \</= 2 macrometastasis in SLNB
Study Locations (1 sites)
KK Women's and Children's Hospital, Singapore, Singapore
Eligibility Criteria
Inclusion Criteria: * female patients aged \>/=55 years old * unifocal cancer on imaging * breast tumour size based on imaging of \</=3cm * no evidence of axillary adenopathy on imaging * patients with strongly positive ER and PR and negative HER2 on biopsy * grade 1-2 tumour on core biopsy * patient who opt for mastectomy Exclusion Criteria: * patients with T3/T4 or stage IV disease, patients with preoperative known N+ disease, bilateral breast cancers, patients planned for neoadjuvant chemotherapy, patients with other malignancies.
Conditions Breast Cancer
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this research study is to evaluate the performance of two experimental tests, namely Liquid Biopsy and Positron Emission Mammography (PEM) in women at high risk of breast cancer. The plan for this study is to assess whether findings from the combination or each individual test can assist radiologists in visualizing and characterizing beast abnormalities. Liquid Biopsy is a blood test that can detect early tumours in patients with malignancies, while PEM is an imaging tool equipped with a high-resolution camera that uses a low dose of injected positron emitting isotope to locate breast tumours. Participation in this study entails a blood draw for Liquid Biopsy test and a PEM imaging exam before undergoing a magnetic resonance imaging (MRI) - guided biopsy for a suspicious breast lesion. If PEM and/or Liquid Biopsy provide accurate information to assist radiologists in visualizing and characterizing breast abnormalities, this method may serve as the first step towards establishing these genomic and new imaging technologies as new diagnostic modalities and ultimately reduce the unnecessary biopsies and anxiety in high-risk populations.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Genetic: Liquid Biopsy — Detects cell-free DNA (cfDNA) circulating in the blood by whole-genome sequencing (WGS). It also detects cfDNA containing epigenetic marks by cell-free methylated DNA immunoprecipitation and high throughput sequencing assays and may determine the concordance of genomic alterations between tumour tissue (if available) and matched plasma samples by WGS.
  • Device: Positron Emission Mammography (PEM) — PEM produces high-sensitivity images of breasts with low levels of F-18 FDG.

Primary Outcomes

  • Evaluating the performance of PEM and Liquid Biopsy in visualizing and characterizing breast abnormalities (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-21
Completion: 2027-07-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Health Network, Toronto
Collaborators: Radialis Inc., The Princess Margaret Cancer Foundation
Principal Investigators:
  • Vivianne Freitas, MD (PRINCIPAL_INVESTIGATOR) - University Health Network, Toronto
Contact Information
Study Contact:
Samira Taeb, MSc
416-946-4501
samira.taeb2@uhn.ca
Vivianne Freitas, MD
416-946-2000
vivianne.freitas@uhn.ca
Samira Taeb, MSc
416-946-4501
samira.taeb2@uhn.ca
University Health Network
Interventions
  • Genetic: Liquid Biopsy — Detects cell-free DNA (cfDNA) circulating in the blood by whole-genome sequencing (WGS). It also detects cfDNA containing epigenetic marks by cell-free methylated DNA immunoprecipitation and high throughput sequencing assays and may determine the concordance of genomic alterations between tumour tissue (if available) and matched plasma samples by WGS.
  • Device: Positron Emission Mammography (PEM) — PEM produces high-sensitivity images of breasts with low levels of F-18 FDG.
Study Locations (1 sites)
University Health Network, Toronto, Ontario M5G 2M9 Canada
Eligibility Criteria
Inclusion Criteria: * Individuals who are older than 18 years of age * Individuals who are planned to undergo an MRI-guided biopsy based on high- risk screening imaging detected lesions * Individuals with the ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * High-risk Individuals with screening-imaging studies without suspicious lesions detected by the standard of care mammogram and/or MRI * Individuals who are pregnant or who think they may be pregnant * Individuals who are breast-feeding * Individuals with known allergies to F-18 FDG
Conditions Solid Tumor Malignancies, Hematologic Ca...
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: 18F-G1 — 18F-G1 is injected intravenously with a dose of 0.06-0.08mCi/kg

Primary Outcomes

  • Number of participants with 18F-G1-related adverse events (AEs). (3 days after the injection of 18F-G1)
  • Tumor uptake of 18F-G1 (40-60 minutes after the injection of 18F-G1)
  • Liver uptake of 18F-G1 (40-60 minutes after the injection of 18F-G1)
  • Lung uptake of 18F-G1 (40-60 minutes after the injection of 18F-G1)
  • Kidney uptake of 18F-G1 (40-60 minutes after the injection of 18F-G1)
  • the granzyme B specificity of 18F-G1 (3 years)
  • Assessing the early predictive value of 18F-G1 PET/CT for immunotherapy response. (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-09-08
Completion: 2028-12-15
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University First Hospital
Contact Information
Study Contact:
Caixia Wu
010-83575252
wucaixia314@163.com
Meng Liu
86-10-83575252
louisa_liu@bjmu.edu.cn
Peking University First Hospital
Interventions
  • Drug: 18F-G1 — 18F-G1 is injected intravenously with a dose of 0.06-0.08mCi/kg
Study Locations (1 sites)
Peking University First Hospital, Beijing, 100034 China
Eligibility Criteria
Inclusion Criteria: 1. Subjects diagnosed with a malignant tumor by histopathology who are going to receive immunotherapy (monotherapy or combined immunotherapy) recommended by the multidisciplinary team. 2. Subjects didn't receive previous immunotherapy. 3. There exists at least one measurable target lesion according to the RECIST 1.1. 4. ECOG performance status≤2. 5. The expected survival time is ≥6 months. 6. Effective contraceptive measures will be adopted during the study period and within 6 months after the study. 7. Willing and able to fully understand and sign the informed consent form. Exclusion Criteria: 1. Women in the preconception period, pregnancy, or lactation period. 2. Combined with other malignant tumor. 3. Diagnosed with autoimmune disease, or have long history of systemic steroid hormone therapy or immunosuppressive therapy. 4. Having a history of severe cardiovascular disease, severe hepatic and renal insufficiency. 5. Receiving radiotherapy or interventional therapy during the immunotherapy. 6. 18F-G1 PET/CT or 18F-FDG PET/CT is not performed in our department, or the interval between baseline imaging and immunotherapy is more than 30 days.
Conditions Advanced Solid Tumor
Phase PHASE1, PHASE2
Enrollment 108
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study now includes a monotherapy cohort targeting visceral lesions and a separate Phase 2 monotherapy cohort for advanced melanoma.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: STX-001 — STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection. Injections may be administered into multiple lesions according to protocol-defined procedures.
  • Biological: Keytruda® — Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.

Primary Outcomes

  • Number and nature of dose-limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients with advanced solid tumors. (From time of informed consent until 30 days after the last dose of investigational product (STX-001).)
  • Occurrence of changes from baseline in patients' clinical safety laboratory values and vital signs to assess the safety and tolerability of STX-001. (From time of informed consent until 30 days after the last dose of investigational product (STX-001).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2024-05-03
Completion: 2028-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 108 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Strand Therapeutics Inc.
Principal Investigators:
  • Jason Luke, MD (STUDY_CHAIR) - Strand Therapeutics
Contact Information
Study Contact:
S Thomas, MS
617-993-9281
stx001.inquiry@strandtx.us
Amy Stolldastice
602-570-2383
astolldastice@honorhealth.com
HonorHealth Research and Innovation Institute
Mini Gill
424-777-0708
MiniG@NextGenOnc.com
NextGen Oncology
Interventions
  • Biological: STX-001 — STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection. Injections may be administered into multiple lesions according to protocol-defined procedures.
  • Biological: Keytruda® — Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.
Study Locations (7 sites)
HonorHealth Research and Innovation Institute, Scottsdale, Arizona 85258 United States
NextGen Oncology, Beverly Hills, California 90212 United States
Cleveland Clinic, Cleveland, Ohio 44195 United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232 United States
The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 United States
Huntsman Cancer Institute - University of Utah, Salt Lake City, Utah 84112 United States
Melanoma Institute Australia, Wollstonecraft, Australia
Eligibility Criteria
General Inclusion Criteria: * ≥ 18 years of age at the time of screening. * Mentally competent and able to understand and sign the informed consent form (ICF). * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Life expectancy of ≥ 12 weeks per the Investigator. * Body weight ˃ 40 kg. * At least 4 weeks from any prior major surgery. * Willing and able to provide blood samples prior to the start of this study. * Has a tumor lesion amenable to injection, must be accessible for pre and post injection biopsy, and the patient must be willing to consent to biopsy, if deemed safe by the Investigator. * Laboratory values (Hematology): Absolute neutrophil count ≥ 1,000 cells/mm3; Platelet count ≥ 75,000 cells/mm3; Hemoglobin ≥ 8.0 g/dL. * Laboratory values (Renal): Serum creatinine \< 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 40 mL/min based on the Cockcroft-Gault glomerular filtration rate estimation * Laboratory values (Coagulation): Prothrombin/International Normalized Ratio (PT/INR) or prothrombin time must be \< 1.5 × ULN; * Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN unless undergoing anticoagulation therapy. * Laboratory values (Liver): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2 × ULN; Bilirubin ≤ 2 × ULN or ≤ 5 × ULN for all patients. Phase 1 Inclusion Criteria: * Histologically or cytologically documented, locally advanced, or metastatic solid tumor. * Disease progression confirmed by imaging or other objective evidence after having received standard treatment or patients with refractory solid tumors. Patients must have progressed or are intolerant of at least one line of prior therapy. Phase 2 Inclusion Criteria (TNBC): * Histologically or cytologically documented findings consistent with TNBC not amenable to curative surgery, radiation, or other therapy. * Prior treatment (for advanced, metastatic or \[neo\]adjuvant) should have included a taxane and/or anthracycline-based therapy and, where appropriate, an approved checkpoint inhibitor. * Has disease other than the injected lesion that is measurable by RECIST 1.1. Phase 2 Inclusion Criteria (melanoma): * Histologically or cytologically documented findings consistent with advanced melanoma not amenable to curative surgery, radiation, or other therapy. Uveal melanoma is excluded. * Patients who are not candidates for or have refused available therapies are also eligible. * Received an anti-programmed death-1 (PD-1) / programmed death ligand-1 (PD-L1) inhibitor as monotherapy or in combination with anti-cytotoxic lymphocyte associated protein 4 (CTLA-4) inhibitor and have either primary or secondary checkpoint inhibitor resistance as per Society for Immunotherapy of Cancer (SITC) consensus definition, unless deemed intolerable by the investigator. Patients with BRAF V600E mutant melanoma should have received a BRAF inhibitor as monotherapy or in combination with other targeted agents (mitogen-activated protein kinase \[MAPK\] kinase \[MEK\] inhibitors), unless deemed intolerable by the investigator. * Has disease other than the injected lesion that is measurable by RECIST 1.1. Phase 1 and 2 Exclusion Criteria: * History of primary immune deficiency. * History of autoimmune disease and/or requiring immunosuppression (except hypothyroidism). * History of History of Grade 3 or higher immune-related adverse events. Patient may be enrolled with Medical Monitor approval. * History of solid organ transplant and taking immunosuppressive medications. * Cardiovascular exclusions: Medical history of an arterial thrombotic event, stroke, or transient ischemic attack within the past 12 months; medical history of symptomatic congestive heart failure (New York Heart Association classes II-IV) or a cardiac arrhythmia that required treatment within the past 12 months; medical history of myocardial infarction or unstable angina within 6 months before Cycle 1 Day 1; QTcF prolongation to \> 470 ms in women and \> 450 ms in men based on a 12-lead electrocardiogram (ECG) in triplicate using the Fridericia formula: QTc = QT / RR1/3. Recent medical concerns exclusions: * Prior direct radiation therapy to the tumor lesion to be injected. * Active use of systemic anticoagulants * Evidence of active infection requiring intravenous (IV) antibiotics during screening requiring therapy within 7 days prior to Cycle 1 Day 1. * Active uncontrolled bleeding, or a bleeding diathesis within 7 days prior to Cycle 1 Day 1. * Serious or non-healing wound, fistula, skin ulcer, or non-healing bone fracture within 7 days prior to Cycle 1 Day 1. * Known human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection. * Virology evaluation should be conducted at screening to include serum HIV antibody, HBc antibody, HBsAg antigen, and HCV antibody. Patients with a positive antibody evaluation for HCV and/or HBc should undergo evaluation to measure HCV RNA or HBV DNA, respectively. * Untreated central nervous system tumor, epidural tumor or metastasis, or brain metastasis. Patients with any primary Central Nervous System (CNS) malignancy including glioma and current, active, progressing CNS malignancy, including carcinomatosis meningitis are excluded. * Patients with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or computed tomography \[CT\] scan) during the screening period and off systemic steroids (for at least 2 weeks prior to first dose). * Another primary malignancy that has not been treated with curative intent, except for non-metastatic cutaneous basal cell or squamous cell carcinoma, or non-muscle invasive bladder cancer. * Serious illness considered by the Investigator as incompatible with participating in this clinical study. * Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of the patient's safety or study results. * Prior IL-12 therapy. * Receipt of any vaccine within 30 days prior to the first dose of study treatment. * Use of another anticancer therapy within 3 weeks prior to Cycle 1 Day 1 or 5 half-lives, whichever is shorter. * Previously enrolled in this study. * Actively enrolled in another clinical study unless it is an observational (noninterventional) clinical study or the follow-up component of an interventional study. * Known severe hypersensitivity (Grade ≥ 3) to study treatment or any of the excipients of the products. * Known psychiatric or substance use disorder that would interfere with the participant's ability to cooperate with the requirements of the study. * Currently pregnant (confirmed with positive pregnancy test), breast-feeding or planning to become pregnant within 60 days following treatment. For women of childbearing potential (WOCBP), a negative serum beta-human chorionic gonadotropin (β-HCG) result must be available within a 72 hour window before the first treatment dose. * Women of childbearing potential not willing to use a highly effective method of contraception. * Unwilling or unable to follow protocol requirements.
Conditions Breast Cancer, Lipofilling, Fat Graft, P...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if a special type of fat graft, made by mixing a person's own fat with platelet-rich fibrin (PRF), works to fix breast shape defects after cancer surgery. PRF is a substance made from a person's own blood that is rich in growth factors, which may help the graft survive better. The main questions it aims to answer are: What percentage of the fat graft's volume remains in place 3 months after radiation therapy? What is the safety of this procedure, including its side effects and any impact on cancer returning? Participants will: * Undergo standard breast-conserving surgery to remove the tumor * Have liposuction (fat removal) from their own belly or thighs * Receive a "lipobolus" (their own fat mixed with PRF) placed into the breast defect during the same surgery * Follow up for 12 months with ultrasound scans, physical exams, and questionnaires (BREASTQ) about their satisfaction and quality of life

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Lipobolus (Autologous Fat + Platelet-Rich Fibrin+Calcium chloride) — The intervention is a single surgical procedure using a "lipobolus" - a modified fat graft made from the participant's own tissues to restore breast shape after cancer surgery. How it is prepared during surgery: About 200 mL of fat is harvested from the participant's belly using liposuction. Separately, 60 mL of blood is drawn and spun in a centrifuge to obtain platelet-rich plasma (PRP). The fat, PRP, and calcium chloride are mixed. Calcium chloride activates the PRP, forming a thick, gel-like fibrin scaffold that traps the fat fragments into a single, stable block. How it is used: The lipobolus is placed directly into the cavity left after breast-conserving cancer surgery. This allows for immediate volume restoration in one operation. What makes it different: Standard fat grafting uses fat alone and often requires 2-3 procedures due to unpredictable abs

Primary Outcomes

  • Percentage of Lipobolus Volume Retention at 3 Months Post-Radiotherapy (3 months after completion of radiotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-13
Completion: 2028-06-03
Eligibility
Age: 18 Years – 69 Years
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Leningrad Regional Clinical Hospital
Contact Information
Study Contact:
Aleksandr Bessonov, PhD
+79061300544
aa.bessonov@lokod.ru
Leningrad Regional Clinical Hospital
Interventions
  • Procedure: Lipobolus (Autologous Fat + Platelet-Rich Fibrin+Calcium chloride) — The intervention is a single surgical procedure using a "lipobolus" - a modified fat graft made from the participant's own tissues to restore breast shape after cancer surgery. How it is prepared during surgery: About 200 mL of fat is harvested from the participant's belly using liposuction. Separately, 60 mL of blood is drawn and spun in a centrifuge to obtain platelet-rich plasma (PRP). The fat, PRP, and calcium chloride are mixed. Calcium chloride activates the PRP, forming a thick, gel-like fibrin scaffold that traps the fat fragments into a single, stable block. How it is used: The lipobolus is placed directly into the cavity left after breast-conserving cancer surgery. This allows for immediate volume restoration in one operation. What makes it different: Standard fat grafting uses fat alone and often requires 2-3 procedures due to unpredictable abs
Study Locations (1 sites)
Leningrad Regional Clinical Hospital, Saint Petersburg, 188663 Russia
Eligibility Criteria
Inclusion Criteria: * Histologically verified breast cancer (BC). * Disease stage from cTis to cT2 according to the TNM classification (AJCC, 8th edition). * Tumor grade G1 or G2. * Estrogen receptor positivity (ER+). * ECOG performance status = 0. * Primary tumor size up to 2 cm, based solely on preoperative examination data (mammography, ultrasound, MRI). * Indications for breast-conserving surgery (BCS) with a breast resection extent determined by a multidisciplinary oncology board. * Submission of an informed voluntary consent (IVC) regarding participation in the study. * Ability to understand and comply with the requirements of the study protocol. Exclusion Criteria: * Male gender. * ECOG ≥ 1. * Multifocal or multicentric tumor. * Grade G3. * Triple-negative or HER2-positive tumor with uncontrolled disease. * Stage cT3 or higher or distant metastases (M1). * Inflammatory breast cancer. * Prior neoadjuvant chemotherapy or hormonal therapy. * Prior radiation therapy to the breast. * Presence of blood coagulation disorders (coagulopathy, thrombocytopathy, thrombocytopenia \< 100 × 10⁹/L). * Taking anticoagulants or antiplatelet agents that cannot be temporarily discontinued. * Presence of active infectious diseases. * Acute autoimmune diseases. * Decompensated comorbidities (diabetes mellitus, cardiovascular diseases, etc.). * Body mass index (BMI) \< 18.5 kg/m² (insufficient adipose tissue volume for liposuction). * Pregnancy or lactation. * Mental illnesses that prevent informed consent. * Known allergy to local anesthetics or sodium citrate.
Conditions Breast Cancer, Adjuvant Therapy
Phase PHASE2
Enrollment 206
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the efficacy of continuation targeted therapy compared with trastuzumab combined with Pyrotinib and capecitabine in postoperative adjuvant therapy of HER-2 positive early breast cancer patients with residual tumor (primary breast tumor/axillary lymph nodes) who did not achieve pCR after neoadjuvant therapy

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pyrotinib+Trastuzumab+Capecitabine — Patients in the experimental arm will receive trastuzumab + pyrotinib + capecitabine
  • Drug: Trastuzumab+Pertuzumab/Trastuzumab — Trastuzumab: Initial loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks. One year of trastuzumab treatment (including: neoadjuvant phase and adjuvant phase) Pertuzumab: 840 mg loading dose followed by 420 mg fixed dose

Primary Outcomes

  • iDFS (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-07-02
Completion: 2027-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: true
Enrollment: 206 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fujian Medical University Union Hospital
Contact Information
Study Contact:
Chuan Wang
13515020716
chuanwang68@qq.com
Silu Wang
18559171530
wangsiluaaron@163.com
Chuan Wang
13515020716
chuanwang68@qq.com
Fujian Medical University Union Hospital
Interventions
  • Drug: Pyrotinib+Trastuzumab+Capecitabine — Patients in the experimental arm will receive trastuzumab + pyrotinib + capecitabine
  • Drug: Trastuzumab+Pertuzumab/Trastuzumab — Trastuzumab: Initial loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks. One year of trastuzumab treatment (including: neoadjuvant phase and adjuvant phase) Pertuzumab: 840 mg loading dose followed by 420 mg fixed dose
Study Locations (1 sites)
Fujian Medical University Union Hospital, Fuzhou, Fujian 350001 China
Eligibility Criteria
Inclusion Criteria: * Female patients aged ≥ 18 years and ≤ 75 years old with primary breast cancer * ECOG score 0 \~ 1 * Breast cancer meets the following criteria: 1)Histologically or pathologically confirmed invasive breast cancer, primary tumor stage determined by standard evaluation methods:cT1-4/N0-3/M0. 2)Pathologically confirmed HER2-expressing positive breast cancer, defined as \> 10% immunoreactive cells with immunohistochemical (IHC) score of 3 + or in situ hybridization (ISH) results of HER2 gene amplification. 3)Known hormone receptor status (ER and PgR). 4)Neoadjuvant therapy (including: at least 9 weeks of trastuzumab treatment and at least 9 weeks of taxane chemotherapy) * Primary breast cancer lesion or lymph node invasive cancer confirmed by pathology after neoadjuvant therapy (residual invasive breast cancer lesion \> 2 cm or axillary lymph node positive with macrometastasis assessed by central laboratory) * No more than 12 weeks between end of surgery (without post-operative radiotherapy) and randomisation or 6 weeks between end of post-operative radiotherapy and randomisation * Required laboratory values including following parameters: ANC: ≥ 1.5 x 109/L Platelet count: ≥ 90 x 109/L Hemoglobin: ≥ 9.0 g/dL Total bilirubin: ≤ 1.5 x upper limit of normal, ULN ALT and AST: ≤ 1.5 x ULN BUN and creatine clearance rate: ≥ 50 mL/min LVEF: ≥ 55% QTcF: \< 470 ms Exclusion Criteria: * 1\) Stage IV (metastatic) breast cancer; * 2\) inflammatory breast cancer; * 3\) Previous anti-tumor therapy or radiotherapy for any malignancy, excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma; * 4\) Receiving anti-tumor therapy in other clinical trials, including bisphosphonate therapy or immunotherapy (except radiotherapy and endocrine therapy during treatment); * 5\) Receiving any anti-tumor therapy within 28 days before enrollment; * 6\) Peripheral neuropathy ≥ Grade 2 as specified by NCI CTCAE; * 7\) Receiving pyrrolidone or other anti-HER2 tyrosine kinase inhibitors; * 8\) Receiving anthracycline therapy with cumulative doses as follows: adriamycin \> 240 mg/m2, epirubicin \> 480 mg/m2; * 9\) Receiving major surgery unrelated to breast cancer before randomization, or the patient has not fully recovered from surgery
Conditions Breast Neoplasms
Phase NA
Enrollment 94
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial aims to evaluate whether an augmented reality (AR)-based medical imaging solution (SKIA-Breast) is non-inferior to conventional ultrasound-guided skin marking in guiding breast-conserving surgery in female patients with breast cancer. Participants will be randomly assigned in a 1:1 ratio to either the AR-based group or the conventional group. All participants will undergo breast-conserving surgery according to their assigned method. The primary outcome is the negative margin resection rate evaluated by histopathological examination. The secondary outcome is the re-excision rate due to positive margins assessed by histopathological examination.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Surgical navigation system with stereotactic guidance — This investigational medical software device utilizes CT imaging data to project the scanned anatomy onto the patient's body, enabling augmented reality-based visualization of the lesion site before surgery
  • Device: General ultrasound imaging system — A general diagnostic ultrasound imaging device that transmits ultrasound energy to the lesion for diagnostic purposes and visualizes the reflected signals. It supports various types of transducers and associated application software packages used for acquiring, displaying, and analyzing ultrasound data.

Primary Outcomes

  • Negative margin resection rate (within 4week after biopsy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-19
Completion: 2027-03-31
Eligibility
Age: 19 Years – 80 Years
Sex: FEMALE
Volunteers: false
Enrollment: 94 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SKIA Inc.
Contact Information
Study Contact:
Jeongmi LEE
+821048856620
jmlee@skia.kr
Ewha Womans University Medical Center
+82 02-2650-5893
jmlee@skia.kr
Ewha Womans University Medical Center
Woosung Lim
Ewha Womans University Medical Center
Interventions
  • Device: Surgical navigation system with stereotactic guidance — This investigational medical software device utilizes CT imaging data to project the scanned anatomy onto the patient's body, enabling augmented reality-based visualization of the lesion site before surgery
  • Device: General ultrasound imaging system — A general diagnostic ultrasound imaging device that transmits ultrasound energy to the lesion for diagnostic purposes and visualizes the reflected signals. It supports various types of transducers and associated application software packages used for acquiring, displaying, and analyzing ultrasound data.
Study Locations (3 sites)
Ewha Womans University Medical Center, Seoul, Gangseo-gu 07804 South Korea
Seoul National University Hospital, Seoul, Jongno-gu South Korea
Yonsei University Health System, Severance Hospital, Seoul, Seodaemun-gu South Korea
Eligibility Criteria
Inclusion Criteria: * Subjects will be enrolled only when all the inclusion criteria are fully met. 1. Subjects who aged 19 to 80 years diagnosed with breast cancer through biopsy. 2. Subjects diagnosed with breast cancer who had both MRI and CT and ultrasound scans. 3. Patients diagnosed with breast cancer who are scheduled to undergo breast-conserving surgery, have not received neoadjuvant chemotherapy, and show no evidence of metastasis to other organs. 4. Tumor size criteria on ultrasound: : 5 mm ≤ tumor size ≤ 30 mm 5. Subjects whose biopsy pathology results are Invasive carcinoma. 6. Subjects who have a single lesion. 7. Subjects who have received a full explanation of the clinical trial fully understand its details, voluntarily decide to participate, and provide written informed consent. Exclusion Criteria: * Subjects will be excluded from enrollment if they meet any of the exclusion criteria. 1. Subjects prohibited from both MRI, CT and Ultrasound scans. 2. Subjects with no lesions visible on CT. 3. Pregnant or lactating(i.e., breastfeeding) subjects. 4. Subjects who are biologically male. 5. Subjects with breast cancer who received neoadjuvant chemotherapy or who have metastasized to other organs 6. Subjects whose biopsy pathology results are Invasive lobular carcinoma 7. Subjects deemed unsuitable for the study according to judgment of the investigator
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase NA
Enrollment 640
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial evaluates remotely delivered, community-aligned weight loss interventions in Latina breast cancer survivors. Breast cancer is the second leading cause of cancer death among women in the US. There are population differences in breast cancer mortality, based on specific risk factors, including obesity. Cancer is the leading cause of death among Latinos, and among Latinas, breast cancer is the leading cause of cancer death. An estimated 80% of Latinas in the United States have overweight/obesity, which is associated with poorer breast cancer outcomes. However, few, if any, effective interventions exist to promote and maintain weight loss in Latina breast cancer survivors. The development of an adaptive program that provides survivors with the support they need, as opposed to what is typically available, to improve breast cancer survivorship.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Sequential Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: ¡Vida! program — Participate in ¡Vida! program
  • Behavioral: ¡Vida! Plus [¡Vida! + Experiential Learning (EL)] — Participate in ¡Vida! Plus program
  • Behavioral: Health Coaching — Receive health coaching
  • Behavioral: Mailed Toolkits — Receive a mailed toolkit of health items

Primary Outcomes

  • Body weight (kg) percent change (Baseline to 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-08
Completion: 2028-03-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 640 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fred Hutchinson Cancer Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Heather Greenlee (PRINCIPAL_INVESTIGATOR) - Fred Hutch/University of Washington Cancer Consortium
Contact Information
Study Contact:
Jenny Whitten-Brannon
206-667-5625
jwhitten@fredhutch.org
Jenny Whitten-Brannon
206-667-5625
jwhitten@fredhutch.org
Fred Hutch/University of Washington Cancer Consortium
Heather Greenlee
Fred Hutch/University of Washington Cancer Consortium
Interventions
  • Behavioral: ¡Vida! program — Participate in ¡Vida! program
  • Behavioral: ¡Vida! Plus [¡Vida! + Experiential Learning (EL)] — Participate in ¡Vida! Plus program
  • Behavioral: Health Coaching — Receive health coaching
  • Behavioral: Mailed Toolkits — Receive a mailed toolkit of health items
Study Locations (1 sites)
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington 98109 United States
Eligibility Criteria
Inclusion Criteria: * Biologically female * Age \>= 18 years * Self-identifies Hispanic/Latina * Able to read and write in Spanish and/or English * Previous diagnosis of stage I-III BC within the past 5 years * No evidence of current, recurrent, or metastatic disease * 60 days post treatment, including chemotherapy, radiation therapy, and cancer-related surgery (NOTE: current allowed therapies include endocrine therapy, CDK4/6 inhibitors (e.g. palbociclib,ribociclib, abemaciclib), HER2-directed therapies (e.g., trastuzumab, neratinib), and monoclonal antibodies (e.g., pertuzumab, pembrolizumab); surgery for breast reconstruction is allowed during the trial) * Body mass index (BMI) \>= 27 kg/m\^2 initially assessed via self-reported height and weight and confirmed prior to randomization via a tape measure and Bluetooth-enabled scale * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * Willingness to participate in all study activities * Access to phone for study contacts * Access to internet to participate in the online program and to be able to sync study devices * Successful completion of at-home baseline assessments prior to randomization Exclusion Criteria: * Body mass index (BMI) \< 27 kg/m\^2 at time of baseline data collection * Diabetic with current use of insulin or sulfonylurea medications (note: current use of metformin is allowed) * Use of glucagon-like peptide-1 (GLP1) receptor agonist medications reported at baseline * Current use of cytotoxic chemotherapy medications (e.g., capecitabine) or drug-antibody conjugates (e.g., trastuzumab emtansine \[T-DM1\], trastuzumab deruxtecan \[T-DXd\]) * Major comorbidities or physical limitations that would preclude from healthy weight loss, reducing energy intake or engaging in PA * Pregnant, breastfeeding, or planning to become pregnant during the study period * Use of exogenous hormones for gender affirmation * For stool sample collection only: Self-reported use of oral or intravenous antibiotics, antifungals, or anti-parasitics during the past 6 months * For stool sample collection only: Presence of self-reported ileostomy or colostomy * For stool sample collection only: Presence of self-reported inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis) * Anticipated major surgical procedure (e.g., hysterectomy) within 3 months after study registration. Breast reconstruction is allowed during study participation. * Concurrent enrollment in another weight loss or physical activity trial
Conditions Improve Sexual Health, Improve Vulvovagi...
Phase NA
Enrollment 50
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

Researchers are doing this study to look at whether sexual health counselling and using non-hormonal moisturizer at the start of ovarian suppression may be able to prevent or reduce side effects such as vaginal dryness and sexual dysfunction. Researchers will compare how effective this prevention intervention works compared to the usual approach, which is to treat these side effects after they start. All participants will also complete surveys about their sexual health. This information will help researchers learn more about the sexual health of women with breast cancer receiving ovarian suppression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: questionnaires — Vaginal Assessment Scale (VAS) \& Vulvar Assessment Scale (VuAS) Breast Clinical Care and Symptom Survey (BCCSS) Female Sexual Function Index (FSFI) Sexual Activity Questionnaire (SAQ) Female Sexual Distress Scale Revised (FSDS-R) Menopausal Symptom Check List (MSCL) Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF) Weekly Non-Hormonal Moisturizer Diary
  • Other: moisturizers — Patients will be provided a list of recommended moisturizers by the female sexual medicine and women's health program (FSMWHP), but will purchase the moisturizers themselves at their local pharmacy.
  • Other: moisturizers — potential vaginal moisturizers include Hyalogyn, Replens, Liquibeads, or Vitamin E capsules

Primary Outcomes

  • Number of participants with a score of 4 or greater in VAS (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-01
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Shari Goldfarb, MD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Shari Goldfarb, MD
646-888-5080
goldfars@mskcc.org
Jeanne Carter, PhD
646-888-5076
Shari Goldfarb, MD
646-888-5080
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Interventions
  • Other: questionnaires — Vaginal Assessment Scale (VAS) \& Vulvar Assessment Scale (VuAS) Breast Clinical Care and Symptom Survey (BCCSS) Female Sexual Function Index (FSFI) Sexual Activity Questionnaire (SAQ) Female Sexual Distress Scale Revised (FSDS-R) Menopausal Symptom Check List (MSCL) Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF) Weekly Non-Hormonal Moisturizer Diary
  • Other: moisturizers — Patients will be provided a list of recommended moisturizers by the female sexual medicine and women's health program (FSMWHP), but will purchase the moisturizers themselves at their local pharmacy.
  • Other: moisturizers — potential vaginal moisturizers include Hyalogyn, Replens, Liquibeads, or Vitamin E capsules
Study Locations (7 sites)
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Cancer Center - Suffolk (Limited Protocol Activities), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: * Women, 18 years of age or older * Breast cancer patients with hormone receptor positive breast cancer , stage 0-III * Premenopausal or perimenopausal women who have either been pregnant or had at least one menstrual period in the last 24 months or have/had an IUD in place * Patients currently on or are being initiated on ovarian suppression * Patients are asymptomatic for vaginal symptoms of estrogen deprivation (i.e. vaginal dryness, dyspareunia, or discomfort \[pain with intercourse or examination\]) and score a 3 or less on the VAS and VuAS Exclusion Criteria: * Postmenopausal women who have been without a period for ≥ 2 years * Patients who score a 4 or above on the VAS and VuAS * Patients already using VVA treatment (e.g. intravaginal estrogen, other non-hormonal moisturizer or suppository), unless discontinued with washout of 4 weeks